Valeo Financial Advisors LLC Takes $218,000 Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• Valeo Financial Advisors LLC has acquired a new stake in IDEXX Laboratories, Inc., purchasing 406 shares valued at approximately $218,000 during the second quarter.
• Insiders have recently sold significant amounts of IDEXX shares, with Director M Anne Szostak selling 2,187 shares for a total of over $1.4 million, reflecting a 89.30% decrease in their ownership.
• IDEXX Laboratories reported an earnings per share (EPS) of $3.63 for the last quarter, surpassing estimates, and has set its FY 2025 guidance between $12.400 to $12.760 EPS.

Valeo Financial Advisors LLC acquired a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 406 shares of the company's stock, valued at approximately $218,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MorganRosel Wealth Management LLC purchased a new position in shares of IDEXX Laboratories in the first quarter valued at about $26,000. Opal Wealth Advisors LLC bought a new stake in IDEXX Laboratories during the 2nd quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. raised its stake in IDEXX Laboratories by 55.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after purchasing an additional 30 shares during the period. Ameritas Advisory Services LLC bought a new stake in IDEXX Laboratories during the 2nd quarter valued at approximately $36,000. Finally, WPG Advisers LLC bought a new stake in IDEXX Laboratories during the 1st quarter valued at approximately $37,000. Institutional investors own 87.84% of the company's stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 2,187 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the transaction, the director owned 262 shares in the company, valued at $169,600.46. The trade was a 89.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Sharon E. Underberg sold 5,450 shares of the business's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the transaction, the executive vice president owned 6,156 shares in the company, valued at $4,011,249.60. This trade represents a 46.96% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $616.15 on Friday. The company's 50-day moving average price is $641.49 and its 200-day moving average price is $541.85. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The company has a market cap of $49.29 billion, a PE ratio of 51.30, a price-to-earnings-growth ratio of 4.07 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.28 by $0.35. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm's revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the business posted $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on IDXX shares. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of IDEXX Laboratories in a report on Wednesday. Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They set a "buy" rating and a $625.00 target price for the company. BTIG Research boosted their price target on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. Leerink Partners lifted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Finally, Wall Street Zen cut IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a report on Sunday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $656.50.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.